EUVIMEDEUVIMED entdecken
Crossref

Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies

Ximu Li, Mengyao Ma, Ni An, Xiaoxuan Yao, Guzailinuer Yasen, Mingyuan Zhong, Zheng Jin, Zhonggui He, Yongjun Wang, Hongzhuo Liu iD

ACS Nano · 2025

DOI: 10.1021/acsnano.4c11928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Ximu Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Lipids, Nanoparticles, Antibodies, Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Department of Education of Liaoning Province, National Natural Science Foundation of China, Shenyang Municipal Bureau of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipidsNanoparticlesAntibodiesVaccinesAnimalsHumansMiceDependovirusHemocyaninsGenetic TherapyMice, Inbred C57BLNanovaccines

Stichwörter der Autor:innen

AAVantidrug antibodieslipid-prodrugnanoparticlespegylated uricase

Substanzen

LipidsAntibodiesVaccinesHemocyaninskeyhole-limpet hemocyaninNanovaccines

Autor:innen und Institutionen

  • Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • Shenyang Sunshine Pharmaceutical Co., Ltd. 3A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang 110027, China.
  • Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.

ORCID-Profile: Hongzhuo Liu

Förderung

  • Department of Education of Liaoning Province
  • National Natural Science Foundation of China
  • Shenyang Municipal Bureau of Science and Technology

Zitieren

APA

Li, X., Ma, M., An, N., Yao, X., Yasen, G., Zhong, M., Jin, Z., He, Z., Wang, Y., & Liu, H. (2025). Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies. ACS Nano. https://doi.org/10.1021/acsnano.4c11928

Vancouver

Li X, Ma M, An N, Yao X, Yasen G, Zhong M, et al. Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies. ACS Nano. 2025. doi:10.1021/acsnano.4c11928

BibTeX
@article{Li2025,
  author = {Li, Ximu and Ma, Mengyao and An, Ni and Yao, Xiaoxuan and Yasen, Guzailinuer and Zhong, Mingyuan and Jin, Zheng and He, Zhonggui and Wang, Yongjun and Liu, Hongzhuo},
  title = {Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies},
  journal = {ACS Nano},
  year = {2025},
  doi = {10.1021/acsnano.4c11928}
}
Kostenlos starten →